How Ruxolitinib Will Change the Future of Vitiligo Treatment

Pearl Grimes, MD, FAAD, and director of the Grimes Center of Medical and Aesthetic Dermatology and the Vitiligo & Pigmentation Institute of Southern California in Los Angeles, explains why the FDA approval of ruxolitinib cream 1.5% is monumental in the treatment of vitiligo.

Related Videos
Related Content

25.1% of Patients Cited “Less Noticeable” Vitiligo in Recent Study

March 21st 2023

The Cutaneous Connection: Deep Dive Into the World of Vitiligo

December 17th 2021

Antioxidants for Vitiligo and Mental Health

March 2nd 2023

Vitiligo in Latin America

March 1st 2023

Vitiligo in Different Ethnicities

February 21st 2023

Applications of Photodynamic Therapy in Pediatric Age

February 16th 2023

25.1% of Patients Cited “Less Noticeable” Vitiligo in Recent Study

March 21st 2023

The Cutaneous Connection: Deep Dive Into the World of Vitiligo

December 17th 2021

Antioxidants for Vitiligo and Mental Health

March 2nd 2023

Vitiligo in Latin America

March 1st 2023

Vitiligo in Different Ethnicities

February 21st 2023

Applications of Photodynamic Therapy in Pediatric Age

February 16th 2023

25.1% of Patients Cited “Less Noticeable” Vitiligo in Recent Study

March 21st 2023

The Cutaneous Connection: Deep Dive Into the World of Vitiligo

December 17th 2021

Antioxidants for Vitiligo and Mental Health

March 2nd 2023

Vitiligo in Latin America

March 1st 2023

Vitiligo in Different Ethnicities

February 21st 2023

Applications of Photodynamic Therapy in Pediatric Age

February 16th 2023
© 2023 MJH Life Sciences

All rights reserved.